• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe
Bradley P. Smith

Bradley P. Smith

Partner, New York

bpsmith@gibsondunn.com

+1 212.351.5376

Brad Smith is a partner in the New York office of Gibson Dunn. He plays a leading role in high-stakes antitrust matters, offering strategic counsel on both merger-related and standalone antitrust issues. Brad is especially noted for his deep expertise in Hart-Scott-Rodino Act pre-merger notification requirements. He has advised clients across sectors including technology, life sciences, finance, transportation, and industrial clients, with completed transactions totaling over $500 billion in value.

View Full Profile

M&A Thirty Days into the Government Shutdown: First Transaction to Close That Launched During the Shutdown

October 30, 2025 | Posted by Ryan A. Murr; Bradley P. Smith; Branden C. Berns; Melanie E. Neary; Topic(s): Government Regulation; M&A; Trends and Insights

Thirty days into the U.S. government shutdown, most federal agencies are operating with only “essential” personnel. The SEC and FTC are running with minimal staffing, authorized to take only limited actions. At the SEC, no registration statements have been declared effective since the shutdown began, and a backlog of more than 1,000 filings is expected to await review once operations resume.

Read More

Primary Sidebar

Gibson Dunn Life Sciences
2025 Outlook Webcast Series
Capital Markets: Click here to view the video recording and program materials.
Royalty Finance: Click here to view the video recording and program materials.
Read ROYALTY REPORT here.

Topics

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

License Agreements

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Disclosure

SEC Updates

Securities Litigation

Shareholder Activism

Tax

Trends and Insights

Editors

Rachel E. Baron

Branden C. Berns

Aaron K. Briggs

Jina L. Choi

Matt Donnelly

Pamela Lawrence Endreny

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Bree Gong

Charlotte Jacobsen

Jin Hee Kim

Wynne Leahy

Jeff Lombard

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Jonathan M. Phillips

Ryan Rott

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Eric B. Sloan

Adam M. Smith

Bradley P. Smith

Karen A. Spindler

Eric J. Stock

Xuan Hong Tran

Terrell Ussing

Jessica Valenzuela

Lindsay Bernsen Wardlaw

Stephen Weissman

Kamia Williams

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.